INPPL1

Overview

INPPL1 (SHIP2) is a phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase that negatively regulates the PI3K/AKT pathway. It appears in the corpus as a co-mutation in BRAF fusion-positive tumors.

Alterations observed in the corpus

  • INPPL1 is mutated in 33% of BRAF fusion-positive colorectal cancers (co-occurring with RNF43 64%, TP53 57%, KMT2D 43%, MSH3 42%, ARID1A 36%) in a tumor-agnostic analysis of 212 patients with BRAF fusions across 52 histologies at MSK PMID:38922339.

Cancer types (linked)

  • Colorectal cancer (within the BRAF fusion-positive subset) — INPPL1 is among the frequent co-mutations in this histology-specific context PMID:38922339.

Co-occurrence and mutual exclusivity

  • Co-mutated with RNF43 (64%), TP53 (57%), KMT2D (43%), MSH3 (42%), and ARID1A (36%) in BRAF fusion-positive colorectal cancers; BRAF fusions are mutually exclusive with other MAPK pathway alterations in this context PMID:38922339.

Therapeutic relevance

  • No direct INPPL1-targeted therapy reported in this corpus PMID:38922339.

Open questions

  • Whether INPPL1 mutations in BRAF fusion-positive colorectal cancers modify response to MEK inhibitors is unexplored in the corpus PMID:38922339.

Sources

This page was processed by crosslinker on 2026-05-04.